Gastrointestinal stromal tumors, version 2.2014: Featured updates to the NCCN Guidelines

Margaret Von Mehren, R. Lor Randall, Robert S. Benjamin, Sarah Boles, Marilyn M. Bui, Ephraim S. Casper, Ernest U. Conrad, Thomas F. DeLaney, Kristen N. Ganjoo, Suzanne George, Ricardo J. Gonzalez, Martin J. Heslin, John M. Kane, Joel Mayerson, Sean V. McGarry, Christian Meyer, Richard J. O'Donnell, Alberto S. Pappo, I. Benjamin Paz, John D. PfeiferRichard F. Riedel, Scott Schuetze, Karen D. Schupak, Herbert S. Schwartz, Brian A. Van Tine, Jeffrey D. Wayne, Mary Anne Bergman, Hema Sundar

Research output: Contribution to journalArticlepeer-review

97 Scopus citations

Abstract

Gastrointestinal stromal tumors (GIST) are the most common soft tissue sarcoma of the gastrointestinal tract, resulting most commonly from KIT or platelet-derived growth factor receptor α (PDGFRα)-activating mutations. These NCCN Guideline Insights high-light the important updates to the NCCN Guidelines for Soft Tissue Sarcoma specific to the management of patients with GIST experiencing disease progression while on imatinib and/or sunitinib.

Original languageEnglish
Pages (from-to)853-862
Number of pages10
JournalJournal of the National Comprehensive Cancer Network : JNCCN
Volume12
Issue number6
DOIs
StatePublished - Jun 1 2014

Fingerprint

Dive into the research topics of 'Gastrointestinal stromal tumors, version 2.2014: Featured updates to the NCCN Guidelines'. Together they form a unique fingerprint.

Cite this